Archive for the ‘Drugs and Outcomes’ Category
Faculty-Researchers at Harvard Medical School (HMS) practicing at Brigham & Women’s Hospital (BWH) Division of Pharmacoepidemiology and Pharmacoeconomics have Netezza’s TwinFin™ data warehouse appliance as their platform for advanced analytics. Their choice of this technology is especially important at a time when many other stakeholders in drug safety and effectiveness (DSE) are planning to upgrade technology. Harvard and BWH have been leaders in pharmacoepidemiological & pharmacoeconomic research since the 1990’s. The lab chief, Dr. Jerry Avorn, is the well-known author of “Powerful Medicines: The Benefits, Risks and Costs of Prescription Drugs”.
Dr. Sebastian Schneeweiss, is the Director for Drug Evaluation and Outcomes Research and Vice Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. The Harvard team of researchers is considered to be an industry bellwether: Here are some of the needs evaluated by the technical lead, Dr. Jeremy Rassen and the sophisticated data mining faculty:
- Computationally intense rapid analysis of claims data—and in the future E.H.R. data—that keeps pace with expanding data input
- Capabilities for in-database analytics
- Ability for accelerated testing of new algorithms
- A system that facilitates automation of continuous drug safety and effectiveness monitoring
- Simplicity of use that minimizes the often bottlenecking need for IT support and database administration
Simplicity of use is especially critical since other technologies often require significant set up and technical support time, both of which can seriously delay the outflow of much needed DSE information to groups involved in Health Economics and Outcomes Research (HEOR), Pharmacovigilance, and Epidemiology.
Dr. Schneeweiss is particularly interested in:
“…comparative safety and effectiveness of pharmaceuticals and biotech products, drug policy and risk management program evaluation, and epidemiologic methods using electronic healthcare databases.”
As such, he expects the use of Netezza technology will help expedite the delivery of timely DSE data and ultimately enhance the ability of care providers to act more quickly and effectively on behalf of patients.
We at Netezza are excited that our collaboration with these notable HMS faculty/researchers has already led to leveraging IBM research development efforts and existing products toward revolutionizing computational pharmacoepidemiology. Advanced research tools for pharmacoepidemiology carry with them the prospect of improved Drug Safety and Effectiveness on a global scale.